Working Toward a Cure
Our researchers contribute to the South Carolina Central Cancer Registry.
Current Trials
Bladder Cancer
Cysview
Description
The purpose of the study is to gather more information on the current use of Blue Light Cystoscopy™ with Cysview® in urologists' practices. This trial is a registry study for patients with bladder cancer who undergo cystoscopy. Cysview is an FDA approved drug imaging agent that is absorbed by malignant cells causing them to appear pink under blue light thus making them easier to see.
Open to enrollment
Posted By: Dr. T. Brian Willard
Posted Date: 5/20/2022
Location: Lexington Urology
Breast Cancer
A012301 LoTam
Description
A012301: LoTam: A Randomized, Phase III Clinical Trial of Low-Dose Tamoxifen for Selected Patients with Molecular Low-risk Early-Stage Breast Cancer.
Testing low dose tamoxifen for invasive breast cancer (LoTam)
Open to enrollment.
Posted By: Dr. Steven Madden
Posted Date: 4/29/2025
Location: Lexington Medical Cancer Center
NRG-CC011
Description
Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors: A Multi-Center Double-Blinded Controlled Trial.
A study to examine computerized training to improve concentration, learning new things, and remembering in breast cancer survivors.
Open to enrollment.
Posted By: Dr. Steven Madden
Posted Date: 5/23/2024
Location: Lexington Medical Cancer Center
S2212 SCARLET
Description
Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study
This phase III trial compares the effects of shorter chemotherapy-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Open to enrollment.
Posted By: Dr. Steven Madden
Posted Date: 8/28/2023
Location: Lexington Medical Cancer Center
A012103
Description
Pembrolizumab vs. observation in people with triple-negative breast cancer who had a pathologic complete response after chemotherapy plus pembrolizumab.
Open to enrollment.
Posted By: Dr. Steven Madden
Posted Date: 7/28/2023
Location: Lexington Medical Cancer Center
A212102
Description
Blinded Reference Set for Multicancer Early Detection Blood Tests. In this study, blood samples will be collected from patients with and without cancer to evaluate tests for early cancer detection.
Open to enrollment.
Posted By: Dr. James Wells
Posted Date: 6/23/2023
Location: Lexington Medical Cancer Center
MA.39 Tailor RT
Description
This study tests regional radiation therapy in patients with low risk breast cancer.
Posted By: Dr. Davis
Posted Date: 9/5/2019
Location: Lexington Medical Cancer Center
Gastrointestinal Cancer
Head & Neck Cancer
Lung Cancer
NRG-LU008
Description
NRG-LU008: Phase III Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed By Concurrent Mediastinal Chemoradiation For Locally Advanced Non-Small Cell Lung Cancer.
This study is testing the addition of high dose, targeted radiation to the usual treatment for locally advanced inoperable non-small cell lung cancer.
Open to enrollment.
Posted By: Dr. Quillin Davis
Posted Date: 7/29/2024
Location: Lexington Medical Cancer Center
Alchemist - A081801
Description
Testing the addition of a type of drug called immunotherapy to the usual chemotherapy treatment for non-small cell lung cancer
Open to enrollment
Posted By: Dr. James Wells
Posted Date: 11/23/2020
Location: Lexington Oncology
Prostate Cancer
S2312
Description
S2312 A Phase III Study of Cabazitaxel with or without Carboplatin in Patients with Metastatic Castrate-resistant Prostate Cancer (MCrPC), Stratified by Aggressive Variant Signature.
This trial is testing whether the addition of carboplatin chemotherapy to cabazitaxel chemotherapy with improve outcomes compared to cabazitaxel alone in people with castrate-resistant prostate cancer that has spread beyond the prostate to other parts of the body.
Open to enrollment.
Posted By: Dr. Scott Graupner
Posted Date: 4/29/2025
Location: Lexington Medical Cancer Center
BRAT
Description
The purpose of the Prostate BRAchyTherapy (BRAT) Registry is to measure clinical outcomes of patients treated with Brachytherapy at Lexington Health (LMC).
Open to enrollment
Posted By: Dr. Quillin Davis
Posted Date: 11/1/2021
Location: Lexington Medical Cancer Center
